- Report
- November 2023
- 119 Pages
Global
From €5747EUR$5,950USD£4,915GBP
- Report
- February 2024
- 175 Pages
Global
From €4830EUR$5,000USD£4,130GBP
- Report
- October 2023
- 180 Pages
Global
From €4733EUR$4,900USD£4,047GBP
- Report
- July 2023
- 111 Pages
Global
From €4347EUR$4,500USD£3,717GBP
- Report
- January 2024
- 152 Pages
Global
From €4105EUR$4,250USD£3,510GBP
- Report
- March 2024
- 175 Pages
Global
From €4830EUR$5,000USD£4,130GBP
- Report
- July 2023
- 66 Pages
Global
From €1207EUR$1,250USD£1,032GBP
- Report
- July 2023
- 86 Pages
Global
From €4782EUR$4,950USD£4,089GBP
- Report
- February 2024
- 120 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- February 2024
- 150 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- November 2022
- 705 Pages
Global
From €6955EUR$7,200USD£5,947GBP
- Report
- February 2023
- 100 Pages
China
From €5747EUR$5,950USD£4,915GBP
- Report
- March 2019
- 66 Pages
Global
From €773EUR$800USD£661GBP
The Small Molecule CMO market is a subset of the Pharmaceutical Manufacturing industry, focusing on the production of small molecule drugs. Small molecule drugs are typically composed of organic molecules, and are used to treat a variety of conditions, from cancer to cardiovascular disease. CMOs provide a range of services, from drug development and clinical trials to manufacturing and packaging. They are often used to reduce the cost and time associated with drug development, as well as to increase the efficiency of the manufacturing process.
CMOs are typically divided into two categories: contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). CMOs focus on the production of small molecule drugs, while CDMOs provide a range of services, from drug development to manufacturing and packaging.
Companies in the Small Molecule CMO market include Boehringer Ingelheim, Catalent, Lonza, Patheon, and Recipharm. Show Less Read more